Levonorgestrel and 17β-estradiol given transdermally for the prevention of postmenopausal osteoporosis

Maturitas

Volumn 50, Issue 2, 2005, Pages 78-85

  Warming, L ^a   Ravn, P ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

17 Estradiol; Levonorgestrel; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; ESTRADIOL; LEVONORGESTREL; OSTEOCALCIN; BIOLOGICAL MARKER; COLLAGEN; GLUTAMYL LYSYL ALANYL HISTIDYL ASPARTYL GLYCYL GLYCYL ARGININE; GLUTAMYL-LYSYL-ALANYL-HISTIDYL-ASPARTYL-GLYCYL-GLYCYL-ARGININE; ORAL CONTRACEPTIVE AGENT; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; ENZYME BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FEMUR NECK; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEASUREMENT; OSTEOPENIA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; UTERUS CANCER; VAGINA BLEEDING; BLOOD; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; URINE;

UCA;

ADMINISTRATION, CUTANEOUS; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN; CONTRACEPTIVES, ORAL, SYNTHETIC; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LEVONORGESTREL; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 11844295471     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.03.016     Document Type: Article

References (18)

1. The writing group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276(17):1389-96.
2. Weiderpass E., Adami H.O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 91(13):1999;1131-1137
3. Ulrich L.G., Barlow D.H., Sturdee D.W., et al. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. UK continuous combined HRT study investigators. Int. J. Gynaecol. Obstet. 59(Suppl 1):1997;S11-S17
4. Stadberg E., Mattsson L.A., Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas. 23(1):1996;31-39
5. Boroditsky R.S. Balancing safety and efficacy focus on endometrial protection. J. Reprod. Med. 45(Suppl 3):2000;273-284
6. Friend D.R. Transdermal delivery of levonorgestrel. Med. Res. Rev. 11(1):1991;49-80
7. Sturdee D.W. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int. J. Clin. Pract. 53(6):1999;468-472
8. Cedars M.I., Judd H.L. Nonoral routes of estrogen administration. Obstet. Gynecol. Clin. North Am. 14(1):1987;269-298
9. Steingold K.A., Matt D.W., DeZiegler D., Sealey J.E., Fratkin M., Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J. Clin. Endocrinol. Metab. 73(2):1991;275-280
10. Paoletti A.M., Pilloni M., Orru M., et al. Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. Maturitas. 42(2):2002;137-147
11. Bounds W., Vessey M., Wiggins P. A randomized double-blind trial of two low dose combined oral contraceptives. Br. J. Obstet. Gynaecol. 86(4):1979;325-329
12. Shulman L.P., Yankov V., Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause. 9(3):2002;195-207
13. Arrenbrecht S., Boermans A.J. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos. Int. 13(2):2002;176-183
14. Delmas P.D., Confavreux E., Garnero P., et al. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos. Int. 11(2):2000;177-187
15. Bjarnason H., Alexandersen P., Christiansen C. Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent. Bone. 30(4):2002;637-642
16. Archer D.F., Pickar J.H. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data. Climacteric. 5(1):2002;45-59
17. Pickar J.H., Bottiglioni F., Archer D.F. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause study group. Climacteric. 1(2):1998;130-136
18. Von Holst T., Salbach B. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. Maturitas. 41(3):2002;231-242